Safety of vaccine adjuvants: Focus on autoimmunity

被引:36
作者
van der Laan, Jan Willem [1 ]
Gould, Sarah [2 ]
Tanir, Jennifer Y. [3 ]
机构
[1] Med Evaluat Board, Utrecht, Netherlands
[2] Sanofi Pasteur, Lyon, France
[3] ILSI Hlth & Environm Sci Inst, ILSI HESI Vaccines & Adjuvants Safety Project Com, Washington, DC 20005 USA
关键词
Vaccines; Autoimmunity; Vaccine adjuvants; Animal models; Safety; TOLL-LIKE RECEPTORS; INNATE IMMUNITY; DISEASES; ARTHRITIS; OIL; INDUCTION; FORMULATION; NARCOLEPSY; BIOMARKERS; PRISTANE;
D O I
10.1016/j.vaccine.2015.01.073
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Questions have been recently raised regarding the safety of vaccine adjuvants, particularly in relation to autoimmunity or autoimmune disease(s)/disorder(s) (AID). The International Life Sciences Institute (ILSI) Health and Environmental Sciences Institute (HESI) formed a scientific committee and convened a 2-day workshop, consisting of technical experts from around the world representing academia, government regulatory agencies, and industry, to investigate and openly discuss the issues around adjuvant safety in vaccines. The types of adjuvants considered included oil-in-water emulsions and toll-like receptor (TLR) agonists. The state of science around the use of animal models and biomarkers for the evaluation and prediction of AID were also discussed. Following extensive literature reviews by the HESI committee, and presentations by experts at the workshop, several key points were identified, including the value of animal models used to study autoimmunity and AID toward studying novel vaccine adjuvants; whether there is scientific evidence indicating an intrinsic risk of autoimmunity and AID with adjuvants, or a higher risk resulting from the mechanism of action; and if there is compelling clinical data linking adjuvants and AID. The tripartite group of experts concluded that there is no compelling evidence supporting the association of vaccine adjuvants with autoimmunity signals. Additionally, it is recommended that future research on the potential effects of vaccine adjuvants on AID should consider carefully the experimental design in animal models particularly if they are to be used in any risk assessment, as an improper design and model could result in misleading information. Finally, studies on the mechanistic aspects and potential biomarkers related to adjuvants and autoimmunity phenomena could be developed.
引用
收藏
页码:1507 / 1514
页数:8
相关论文
共 48 条
[1]  
[Anonymous], 2012, WORKSH ADJ VACC FOC
[2]  
Baradkar Vasant, 2011, Trop Parasitol, V1, P141, DOI 10.4103/2229-5070.86969
[3]  
Benstetter M, 2011, EUROPEAN MED AGENCY
[4]  
CANNON GW, 1993, J RHEUMATOL, V20, P7
[5]   The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats [J].
Carlson, BC ;
Jansson, ÅM ;
Larsson, A ;
Bucht, A ;
Lorentzen, JC .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (06) :2057-2065
[6]   Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus [J].
Christensen, Sean R. ;
Shupe, Jonathan ;
Nickerson, Kevin ;
Kashgarian, Michael ;
Flavell, Richard A. ;
Shlomchik, Mark J. .
IMMUNITY, 2006, 25 (03) :417-428
[7]   MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases [J].
Dai, Rujuan ;
Ahmed, S. Ansar .
TRANSLATIONAL RESEARCH, 2011, 157 (04) :163-179
[8]   Knockout of Toll-Like Receptor-2 Attenuates Both the Proinflammatory State of Diabetes and Incipient Diabetic Nephropathy [J].
Devaraj, Sridevi ;
Tobias, Peter ;
Kasinath, Balakuntalam S. ;
Ramsamooj, Rajendra ;
Afify, Alaa ;
Jialal, Ishwarlal .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2011, 31 (08) :1796-U220
[9]  
European Medicines Agency, 2013, EUR PUBL ASS REP AFL
[10]  
European Medicines Agency, EUR PUBL ASS REP PAN